Latest Articles
Selinexor Maintenance Misses PFS End Point in TP53 Wild-Type Endometrial Cancer - onclive.com
Selinexor Maintenance Misses PFS End Point in TP53 Wild-Type Endometrial Cancer onclive.com
Published: July 31, 2026, 5:22 p.m.
Selinexor Misses PFS End Point in TP53 Wild-Type Endometrial Cancer - CancerNetwork
Selinexor Misses PFS End Point in TP53 Wild-Type Endometrial Cancer CancerNetwork
Published: July 31, 2026, 2:37 p.m.
Selinexor Misses PFS End Point in TP53 Wild-Type Endometrial Cancer - cancernetwork.com
Selinexor Misses PFS End Point in TP53 Wild-Type Endometrial Cancer cancernetwork.com
Published: July 31, 2026, 2:37 p.m.
H.C. Wainwright cuts Karyopharm stock rating on trial miss By Investing.com - Investing.com Australia
H.C. Wainwright cuts Karyopharm stock rating on trial miss By Investing.com Investing.com Australia
Published: July 31, 2026, 11:35 a.m.
Selinexor Misses Primary Endpoint in Endometrial Cancer Trial - Medical Professionals Reference
Selinexor Misses Primary Endpoint in Endometrial Cancer Trial Medical Professionals Reference
Published: July 31, 2026, 4 a.m.
Selinexor Misses Primary Endpoint in Endometrial Cancer Trial - empr.com
Selinexor Misses Primary Endpoint in Endometrial Cancer Trial empr.com
Published: July 31, 2026, 4 a.m.
Lotus Endometriosis Institute Releases Guide On Missed Diagnosis Amid Care Gaps - usatoday.com
Lotus Endometriosis Institute Releases Guide On Missed Diagnosis Amid Care Gaps usatoday.com
Published: July 30, 2026, 11:49 p.m.
Lotus Endometriosis Institute Releases Guide On Missed Diagnosis Amid Care Gaps - USA Today
Lotus Endometriosis Institute Releases Guide On Missed Diagnosis Amid Care Gaps USA Today
Published: July 30, 2026, 11:49 p.m.
Karyopharm slumps after Xpovio misses mark in Phase III endometrial cancer study - FirstWord Pharma
Karyopharm slumps after Xpovio misses mark in Phase III endometrial cancer study FirstWord Pharma
Published: July 30, 2026, 9:59 p.m.
Karyopharm endometrial cancer trial misses primary endpoint By Investing.com - Investing.com Nigeria
Karyopharm endometrial cancer trial misses primary endpoint By Investing.com Investing.com Nigeria
Published: July 30, 2026, 8:42 p.m.
Link copied to clipboard!